NYSEHealth CareHealth Care EquipmentS&P MidCap 400
$319.21
-1.90 (-0.59%)
Close of Nov 06, 2026 · end-of-day data
PEN 8-K filings in 2025
Every material Form 8-K Penumbra filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Penumbra appointed Shruthi Narayan as President effective September 1, 2025, while Adam Elsesser continues as Chairman and CEO. The filing also discloses a related-person IT services arrangement with a company led by Ms. Narayan's spouse, and an equity grant of about $2.5 million to Ms. Narayan.
Shruthi Narayan appointed President effective September 1, 2025; board action dated August 22, 2025
Equity grant of restricted stock units valued at approximately $2.5 million, vesting in equal annual installments over four years
Payments to N28 Technologies, led by Ms. Narayan's spouse, total approximately $2 million since January 1, 2024
Penumbra reported first quarter 2025 revenue of $324.1 million, up 16.3% from a year earlier, and net income of $39.2 million, compared with $11.0 million in the first quarter of 2024. The company reiterated its full-year 2025 revenue guidance of $1,340 million to $1,360 million and raised its U.S. Thrombectomy growth outlook to 20% to 21%.
Revenue $324.1 million, up 16.3% (16.9% in constant currency) from $278.7 million in Q1 2024
Net income $39.2 million, or $1.00 diluted EPS, versus $11.0 million, or $0.28 diluted EPS, a year earlier
Full-year 2025 revenue guidance of $1,340 million to $1,360 million reiterated
U.S. Thrombectomy growth guidance raised to 20% to 21% from 19% to 20%
Penumbra said director Don Kassing notified the company on February 14, 2025 that he will retire from its board effective April 1, 2025. The filing states his decision did not involve any disagreement with the company, and it contains no financial results or guidance.
Don Kassing, a board member since 2008 and Presiding Director since 2015, will retire effective April 1, 2025.
Notice to the company was dated February 14, 2025; the press release was issued February 21, 2025.
Board chair, president and CEO Adam Elsesser thanked Kassing for his service over 17 years.
The filing states Kassing's decision did not involve any disagreement with the company.
Penumbra reported fourth-quarter and full-year 2024 results, with revenue up 10.8% in the quarter and 12.9% for the year. Net income fell sharply, to $14.0 million for the year from $91.0 million in 2023, largely due to a $76.9 million impairment charge tied to its Immersive Healthcare business. The company projected 2025 revenue of $1,340.0 million to $1,360.0 million, growth of 12% to 14%.
Q4 2024 revenue was $315.5 million, up 10.8% from $284.7 million; Q4 net income was $33.7 million versus $54.2 million a year earlier.
Full-year 2024 revenue was $1,194.6 million, up 12.9%, but income from operations fell to $9.3 million from $73.6 million.
The 2024 results include a $76.9 million impairment charge and a $5.8 million Italian government payback provision.
For 2025, the company projects total revenue of $1,340.0 million to $1,360.0 million and operating margin of 13% to 14%.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Penumbra filing is on SEC EDGAR ↗. 8-K briefs of other companies →